Results of a clinical study of the drug efficacy and safety for intravesical administration based on bacteriophages in therapy in patients with chronic recurrent cystitis

Cover Page

Cite item

Full Text

Abstract

Background. Urinary tract infections remain one of the urgent problems in the aspect of qualified medical care. The causative agents of nosocomial infections are becoming more and more resistant to the drugs used, while the rate of new drugs synthesis is lower than the rate of development of antibiotic resistance. Routine and empirical prevention of recurrent urinary tract infections is often ineffective.

Aim. To study the efficacy and safety of intravesical application of the drug based on bacteriophages in therapy in patients with chronic recurrent cystitis.

Materials and methods. A clinical study was carried out to study the efficacy and safety of the drug for intravesical administration based on bacteriophages in therapy in patients with chronic recurrent cystitis. The study included 75 patients who were divided into 3 groups in a 1: 1: 1 ratio. In the main group, the drug for intravesical administration based on bacteriophages, as well as rectal suppositories with bacteriophages were used; in the control group – only a drug for intravesical administration based on bacteriophages or rectal suppositories with bacteriophages. On visits 1-4, all patients underwent a clinical blood test, general urine analysis, bacteriological urine analysis, as well as urine analysis by the polymerase chain reaction method. The analysis of the patients condition in groups was carried out according to the dynamics of main clinical symptoms changes, data from validated scales for assessing pelvic pain and urgency/frequency of urination and assessment of symptoms of acute cystitis (Acute Cystitis Symptom Score – ACSS), as well as the dynamics of changes in objective parameters of laboratory studies and possible changes in sensitivity uropathogens to antibacterial drugs.

Results. The average age of the patients included in the study was 50.6 years. In all 3 groups, bacteriological examination of urine showed a predominant growth of Escherichia coli (3×104 CFU/ml). In the course of the study, there was a good tolerance to therapy, a decrease in clinical symptoms, as well as a significant decrease in the total score according to the pelvic pain scale and urgency/frequency of urination and the ACSS scale in all patients.

Conclusion. The emergence of a large number of microorganisms resistant to various antibiotics and their rapid spread in the environment has led to an increase in scientific interest in bacteriophage therapy as an alternative method of treatment. The overall subjective effectiveness of the therapy in our study was more than 80%, safety - 100%. Further research will allow for a personalized approach to the treatment of infectious diseases of the urinary system.

About the authors

Andrei V. Zaitsev

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: zaitcevandrew@mail.ru
ORCID iD: 0000-0003-3044-1424

D. Sci. (Med.), Prof.

Russian Federation, Moscow; Moscow

Oksana A. Arefeva

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital; Research Institute of Health Organization and Medical Management

Email: oksadoc@yandex.ru
ORCID iD: 0000-0003-2309-2094

Cand. Sci. (Med.)

Congo, Moscow; Moscow; Moscow

Natalia A. Sazonona

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: natsazonova@outlook.com
ORCID iD: 0000-0003-1673-1089

Graduate Student

Russian Federation, Moscow; Moscow

Vladimir D. Melnikov

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: vladimir-m95@mail.ru
ORCID iD: 0000-0002-2403-4331

Graduate Student

Russian Federation, Moscow; Moscow

Yuriy A. Kim

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: dockimyura@gmail.com
ORCID iD: 0000-0001-6390-3408

Graduate Student

Russian Federation, Moscow; Moscow

Arseniy A. Shiryaev

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: eschief2@gmail.com
ORCID iD: 0000-0003-0680-9460

Graduate Student

Russian Federation, Moscow; Moscow

Alexander O. Vasilyev

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital; Research Institute of Health Organization and Medical Management

Email: alexvasilyev@me.com
ORCID iD: 0000-0001-5468-0011

Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow; Moscow

Igor O. Gritskov

Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: grickoff@mail.ru
ORCID iD: 0000-0002-4708-1683

Resident

Russian Federation, Moscow

Alexander V. Govorov

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: dr.govorov@gmail.com
ORCID iD: 0000-0003-3299-0574

D. Sci. (Med.), Prof.

Russian Federation, Moscow; Moscow

Dmitry Yu. Pushkar

Yevdokimov Moscow State University of Medicine and Dentistry; Spasokukotsky City Clinical Hospital

Email: pushkardm@mail.ru
ORCID iD: 0000-0002-6096-5723

D. Sci. (Med.), Prof., Acad. RAS

Russian Federation, Moscow; Moscow

References

  1. Tandogdu Z, Wagenlehner FME. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73-9. doi: 10.1097/QCO.0000000000000228
  2. Ikäheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996(22):91-9. doi: 10.1093/clinids/22.1.91
  3. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol. 2005;173:1281-7. doi: 10.1097/01.ju.0000155596.98780.82
  4. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151(12):1194-205. doi: 10.1093/oxfordjournals.aje.a010170
  5. Magistro G, Marcon J, Schubert S, et al. Pathogenese der harnwegsinfektion ein update. Der Urologe. 2017;56(6):720-7. doi: 10.1007/s00120-017-0391-7
  6. Hooton TM, Scholes D, Hughes JP. A prospective study of risk factors for symptomatic urinary tract infection in young women. New Engl J Med. 1996;335(7):468-74. doi: 10.1056/NEJM199608153350703
  7. Scholes D, Hawn TR, Roberts PL, et al. Family history and risk of recurrent cystitis and pyelonephritis in women. J Urol. 2010;184(2):564-9. doi: 10.1016/j.juro.2010.03.139
  8. Hooton TM, Stapleton AE, Roberts PL Perineal anatomy and urine-voiding characteristics of young women with and without recurrent urinary tract infections. Clin Infect Dis. 1999;29(6):1600-1. doi: 10.1086/313528
  9. Albert X, Huertas I, Pereiro´ II, et al. Antibiotics for preventing recurrent urinary tract infection in nonpregnant women. Cochrane Database Syst Rev. 2004;2004:CD001209. DOI;10.1002/14651858.CD001209.pub2
  10. Ny S, Edquist P, Dumpis U, et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25-34. doi: 10.1016/j.jgar.2018.11.004
  11. Wojno KJ, Baunoch D, Luke N, et al. Multiplex PCR Based Urinary Tract Infection (UTI) Analysis Compared to Traditional Urine Culture in Identifying Significant Pathogens in Symptomatic Patients. Urology. 2020;136:119-26. doi: 10.1016/j.urology.2019.10.018
  12. Lee SJ, Choe HS, Na YG. Guidelines of the Korean association of urogenital tract infection and inflammation: recurrent urinary tract infection. Urogenit Tract Infect. 2017;12(1):7. doi: 10.14777/uti.2017.12.1.7
  13. Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509-15. doi: 10.1001/jamainternmed.2018.4204
  14. Finh SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and escherichia coli urinary tract infection in young women. Am J Epidemiol. 1996;144(5):512-20. doi: 10.1093/oxfordjournals.aje.a008958
  15. Schmidt DR, Sobota AE. An examination of the anti-adherence activity of cranberry juice on urinary and nonurinary bacterial isolates. Microbios. 1988;55(224-225):173-81.
  16. Stapleton AE, Dziura J, Hooton TM, et al. Recurrent urinary tract infection and urinary escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc. 2012;87(2):143-50. doi: 10.1016/j.mayocp.2011.10.006
  17. Beerepoot MAJ, ter Riet G, Nys S, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med. 2011;171(14):1270-8. doi: 10.1001/archinternmed.2011.306
  18. Avorn J, Monane M, Gurwitz JH, et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 1994;271(10):751-4. doi: 10.1001/jama.1994.03510340041031
  19. Lenger SM, Bradley MS, Thomas DA, et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Gynecol. 2020;223(2):265.e1-265.e13. doi: 10.1016/j.ajog.2020.05.048
  20. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79-84. doi: 10.1007/s00345-013-1091-6
  21. Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urology. 2011;59(4):645-51. doi: 10.1016/j.eururo.2010.12.039
  22. Interdisziplinäre S3 leitlinie: epidemiologie, diagnostik, therapie, prevention und management unkomplizierter, bakterieller, ambulant erworbener harnwegsinfektionen bei erwachsenen patienten. AWMF-Register-Nr. 043/044 2017 (Version 1.1-2).
  23. Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J. 2021. doi: 10.1007/s00192-021-04849-0
  24. Larsson B, Jonasson A, Fianu S. Prophylactic effect of UVA-E in women with recurrent cystitis: a preliminary report. Curr Ther Res. 1993;53(4):441-3. doi: 10.1016/S0011-393X(05)80204-8
  25. Albrecht U, Goos K-H, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin. 2007;23(10):2415-22. doi: 10.1185/030079907X233089
  26. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New Engl J Med. 1993(329):753-6. doi: 10.1056/NEJM199309093291102
  27. Eriksen BC. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180(5):1072-9. doi: 10.1016/s0002-9378(99)70597-1
  28. Raz R, Colodner R, Rohana Y, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis. 2003;36(11):1362-8. doi: 10.1086/374341
  29. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19(6):451-6. doi: 10.1016/s0924-8579(02)00106-1
  30. Nestler S, Grüne B, Schilchegger L, et al. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study. Int Urol Nephrol. 2021;53(11):2267-72. doi: 10.1007/s11255-021-02987-4
  31. Clarke AL, Soir S de, Jones JD. The safety and efficacy of phage therapy for bone and joint infections: a systematic review. Antibiotics (Basel, Switzerland). 2020;9(11):795. doi: 10.3390/antibiotics9110795.
  32. Gibb BP, Hadjiargyrou M. Bacteriophage therapy for bone and joint infections. Bone Joint J. 2021;103-B(2):234-44. doi: 10.1302/0301-620X.103B2.BJJ-2020-0452.R2
  33. Leitner L, Ujmajuridze A, Chanishvili N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3):427-36. doi: 10.1016/S1473-3099(20)30330-3
  34. Bao Y, Al KF, Chanyi RM, et al. Questions and challenges associated with studying the microbiome of the urinary tract. Ann Transl Med. 2017;5(2):33. doi: 10.21037/atm.2016.12.14
  35. Yilmaz S, Allgaier M, Hugenholtz P. Multiple displacement amplification compromises quantitative analysis of metagenomes. Nat Methods. 2010;7(12):943-4. doi: 10.1038/nmeth1210-943
  36. Panek M, Cipcic Paljetak H, Baresic A, et al. Methodology challenges in studying human gut microbiota – effects of collection, storage, DNA extraction and next generation sequencing technologies. Sci Rep. 2018;8(1):5143. doi: 10.1038/s41598-018-23296-4
  37. Brubaker L, Wolfe A. The urinary microbiota: a paradigm shift for bladder disorders? Curr Opin Obstet Gynecol. 2016;28(5):407-12. doi: 10.1097/GCO.0000000000000298
  38. Santiago-Rodriguez TM, Ly M, Bonilla N, Pride DT. The human urine virome in association with urinary tract infections. Front Microbiol. 2015;6:14. doi: 10.3389/fmicb.2015.00014
  39. Malki K, Shapiro JW, Price TK, et al. Genomes of gardnerella strains reveal an abundance of prophages within the bladder microbiome. PLoS One. 2016;11(11):e0166757. doi: 10.1371/journal.pone.0166757
  40. Miller-Ensminger T, Garretto A, Brenner J, et al. Bacteriophages of the urinary microbiome. J Bacteriol. 2018;200(7):e00738-17. doi: 10.1128/JB.00738-17
  41. Moustafa A, Li W, Singh H, et al. Microbial metagenome of urinary tract infection. Sci Rep. 2018;8(1):4333. doi: 10.1038/s41598-018-22660-8

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Dynamics of changes in the final scores according to validated scales in patients of the 1st (main) group.

Download (115KB)
Indexing metadata
3. Fig. 2. Dynamics of changes in the final scores according to validated scales in patients of the 2nd (control) group.

Download (124KB)
Indexing metadata
4. Fig. 3. Dynamics of changes in the final scores according to validated scales in patients of the 3rd (control) group.

Download (129KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».